Idarubicin
Topoisomerase Inhibitor
DB01177
Approved Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
1
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Details
DrugBank ID
DB01177 ↗
Approval Date
1997-02-17
Molecular Weight
497.4939 g/mol
Drug Class
Topoisomerase Inhibitor
ATC Codes
L01DB06
Synonyms
4-Demethoxydaunomycin, 4-Demethoxydaunorubicin, Idarubicina
PubChem
CID: 42890 ↗
ChEMBL
CHEMBL1117 ↗
SMILES
C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O
ADMET Profile
Computing properties…